How does the iPrEx study work?
The study is designed to determine whether tenofovir/emtricitabine is effective in preventing HIV infection when combined with safer sex counseling and condom use. The study is also examining side effects from the study drug. Participants at each site are randomly divided into two groups. Both groups receive medical care for any sexually transmitted infections, along with condoms and counseling on how to prevent HIV infection. One group also receives the study drug tenofovir/emtricitabine once daily, while the other receives a placebo (sugar pill). No one, including the study personnel, know who is receiving the treatment and who is receiving the placebo until the study is finished. Participants receive intensive counseling in safer sex practices. All participants are monitored throughout the study (until approximately mid-2010), and for up to six months afterward.
